Incyte Corporation

INCY

Healthcare Biotechnology

Incyte Corporation’s revenue for fiscal 2025 (year ended December 2025) was $5.1 billion, up 21.2% from fiscal 2024.

Revenue
+14.0%
EPS
−277.9%
Free cash flow
−233.0%
Total debt
−10.5%

Quarter to September 2026, against a year earlier

121.89 0.38 −0.31%
Market cap
$24.9B
P/E
58.1×
Fwd P/E
57.3×
Dividend yield
—
F-score
9/9
ROIC
21.6%
Net debt / EBITDA
−2.2×
Dividend safety
n/a
Older periods Dec '25 Mar '26 Jun '26 Sep '26
P/E ratio

+8 more quarters

14.97 12.89 13.94 57.82
P/S ratio
3.75 3.50 3.90 4.10
P/FCF ratio
14.50 13.20 12.02 36.28
P/Operating CF
35.49 50.80 44.74 (36.52)
P/B ratio
3.73 3.34 3.58 4.37
EV/Sales
3.06 2.76 3.13 3.47
EV/EBITDA
9.79 8.67 9.71 28.76
EV/FCF
11.84 10.41 9.64 30.67
Current Ratio
3.32 3.68 4.59 3.84
Net Debt/EBITDA
(9.87) (12.27) (6.22) 5.59
Debt/Equity
0.01 0.01 0.00 0.00
Earnings Yield
6.68% 7.76% 7.17% 1.73%
Free Cash Flow Yield
6.90% 7.57% 8.32% 2.76%
Free Cash Flow per Share
2.67 1.78 2.47 (3.40)
Book value per Share
26.47 28.21 31.66 27.76
Free Cash Flow
521.42 354.15 495.25 (690.95)
EV/EBIT
10.39 9.18 10.24 33.28
Other line items

Show all line items

Columns are period end dates · fundamentals updated 2 Nov 2026